gemcitabine,cisplatin,carboplatin,enfortumab,pembrolizumab
astellas,seagen,merck
['pembro', 'ev-103']
 colleague presenting updated data on ev-103 cohort a. impressive durable responses to ev+pembro in cis-ineligible patients. honored to have participated in this transformative study leading to fda approval of the combo #asco23 
GU Oncologist at @UHhospitals